Brookfield Asset Management Inc. Repligen Corp Transaction History

Brookfield Asset Management Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Sep 25, 2023	SELL	$138.42 - $180.31 $634,240 - $826,180	-4,582 Reduced 56.37%	3,546 $501,000
Q2 2023 Aug 14, 2023	SELL	$138.42 - $180.31 $634,240 - $826,180	-4,582 Reduced 56.37%	3,546 $501,000
Q1 2023 Sep 25, 2023	BUY	$154.26 - $198.1 $706,819 - $907,694	4,582 Added 129.22%	8,128 $1.37 Million
Q1 2023 May 15, 2023	BUY	$154.26 - $198.1 $1.25 Million - $1.61 Million	8,128 New	8,128 $1.37 Million
Q2 2022 Nov 16, 2022	BUY	$140.68 - $188.02 $3.13 Million - $4.18 Million	22,251 New	22,251 $3.61 Million
Q2 2022 Aug 15, 2022	BUY	$140.68 - $188.02 $2.03 Million - $2.72 Million	14,454 Added 185.38%	22,251 $3.61 Million
Q3 2021 Nov 16, 2021	BUY	$194.77 - $324.21 $168,670 - $280,765	866 Added 12.49%	7,797 $2.25 Million
Q2 2021 Aug 17, 2021	BUY	$165.87 - $220.95 $1.15 Million - $1.53 Million	6,931 New	6,931 $1.38 Million

488

54.2M

341K

235K

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $8.02B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Brookfield Asset Management Inc. with notifications on news.